Novo Nordisk A/S Securities Class Action Investigation, Deadline September 30, 2025.

Faruqi & Faruqi, a national securities law firm, is investigating Novo Nordisk A/S over potential claims related to securities purchases between May 7, 2025, and July 28, 2025. Investors who suffered losses are encouraged to contact James (Josh) Wilson directly to discuss their options. The deadline to seek lead plaintiff status is September 30, 2025.

Novo Nordisk A/S (NVO) is facing a class action lawsuit alleging securities fraud, with investors urged to contact legal firms to discuss their options. The lawsuit, filed on behalf of investors who purchased Novo Nordisk securities between May 7, 2025, and July 28, 2025, alleges that the company made misleading statements about its growth potential and the impact of compounded GLP-1s on its market expansion [1].

The complaint claims that Novo Nordisk overstated its ability to capitalize on the compounded market and understated the impact of the personalization exception to the compounded GLP-1 exclusion. On July 29, 2025, the company announced it was lowering its sales and profit outlook for the second quarter of fiscal year 2025, citing lower growth expectations for Ozempic and Wegovy due to market expansion slowdown, competition, and the alleged use of compounded GLP-1s [2]. This news led to a significant drop in Novo Nordisk's stock price, declining by $15.06, or 21.8%, to close at $53.94 per share on July 29, 2025 [3].

Investors who suffered losses during this period are encouraged to contact Faruqi & Faruqi, LLP, a leading national securities law firm, to discuss their legal rights. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995 and is investigating potential claims against Novo Nordisk [3]. The deadline to seek lead plaintiff status in the lawsuit is September 30, 2025 [3].

Novo Nordisk's stock price has been under pressure due to increased competition and regulatory challenges related to the use of compounded GLP-1s. The company's outgoing CEO, Lars Fruergaard Jorgensen, acknowledged that layoffs may be necessary to lower costs and maintain profitability [2]. The new CEO, Mike Doustdar, will take over the top job on August 5, 2025 [2].

Investors should carefully consider the potential impact of the class action lawsuit and the recent guidance adjustments on Novo Nordisk's stock price and financial performance. The company's ability to navigate these challenges will be crucial for its future growth prospects.

References:
[1] https://www.ainvest.com/news/novo-nordisk-investors-file-securities-fraud-class-action-lawsuit-2508/
[2] https://www.thetimes.com/business-money/companies/article/novo-nordisk-danish-drug-cost-cut-ozempic-wegovy-frds8v8kb
[3] https://www.morningstar.com/news/pr-newswire/20250803ny42967/faruqi-faruqi-reminds-novo-nordisk-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-september-30-2025-nvo